当前位置: 首页 >> 检索结果
21. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
作者: Chao Jiang.;Zixu Zhao.;Zejun Yang.;Yiping Wang.;Yang Xu.;Hui Xu.;Hang Guo.;Chi Wang.;Liu He.;Shijun Xia.;Xiangyi Kong.;Wenli Dai.;Junmeng Zhang.;Song Zuo.;Xiaoxia Liu.;Xueyuan Guo.;Nian Liu.;Songnan Li.;Ning Zhou.;Chenxi Jiang.;Ribo Tang.;Caihua Sang.;Paul C Zei.;Deyong Long.;Xin Du.;Jianzeng Dong.;Laurent Macle.;Changsheng Ma.
来源: Circulation. 2026年153卷5期297-306页
Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors.
22. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
作者: Xiaowen Wang.;Maria A Pabon.;Tracy T Makuvire.;Reziwanguli Maimaiti.;Theodore P Abraham.;Roberto Barriales-Villa.;Brian L Claggett.;Caroline J Coats.;Martin S Maron.;Ahmad Masri.;Benjamin Meder.;Michael E Nassif.;Iacopo Olivotto.;Anjali T Owens.;Sara Saberi.;Daniel L Jacoby.;Stephen B Heitner.;Stuart Kupfer.;Fady I Malik.;Amy Wohltman.;Scott D Solomon.;Sheila M Hegde.
来源: Circ Heart Fail. 2026年19卷1期e013918页
Women with obstructive hypertrophic cardiomyopathy often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown.
23. Randomized Comparison of Online Motivational Themes in Clinical Trial Recruitment.
作者: Tamunotonye Harry.;Zaib Hussain.;Jingyi Cao.;Ruth-Alma N Turkson-Ocran.;Stephen P Juraschek.;Erin D Michos.;Hailey N Miller.;Timothy P Lahey.;Timothy B Plante.;Yuanyuan Feng.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012945页
Targeted, digital recruitment strategies such as tailored websites using motivational themes may improve recruitment in clinical trials, but their effectiveness remains unclear. We hypothesized that themes emphasizing community well-being, personal health benefits, or access to perks would increase engagement and prescreening sign-ups compared with a standard contribution to science message in a clinical trial focused on Black adults.
24. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial.
作者: Sergio Raposeiras-Roubín.;Emad Abu Assi.;César Jiménez Méndez.;Ester Mínguez de la Guía.;José Ángel Pérez Rivera.;Marta Marcos Mangas.;Ana Ayesta.;Aitor Uribarri.;Pablo Jorge Pérez.;Pablo José Antúnez Muinos.;Clara Bonanad Lozano.;Anna Carrasquer.;Ana Viana-Tejedor.;Pablo Domínguez Erquicia.;Alberto Villar Ruiz.;Macarena López Vázquez.;Lara Aguilar Iglesias.;Alberto Alén Andrémar.;Maria Vidal Burdeus.;Marta Maria Martin Cabeza.;María Cristina González Cambeiro.;Daznia Bompart.;Juan Carlos Gómez Polo.;Marina Teresa García García.;Ana Merino Merino.;José Rozado.;José Antonio Panera de la Mano.;Francisco Salmerón Martínez.;Ester Sánchez Corral.;Isabel Santos Sánchez.;Ángel Víctor Hernández-Martos.;Andrés Antelo Abejón.;Andrés Iñiguez Romo.;Miguel Corbi-Pascual.;Albert Ariza-Solé.
来源: Circulation. 2026年153卷3期140-149页
Current guidelines recommend a stepwise strategy to achieve low-density lipoprotein cholesterol (LDL-C) goals after acute coronary syndrome (ACS). Earlier intensive strategies based on a combination of lipid-lowering therapies (LLTs) could be useful from the onset of ACS. However, the role of bempedoic acid in ACS, particularly when combined with high-intensity statins and ezetimibe, remains uncertain. The aim of ES-BempedACS (Efficacy and Security of Bempedoic Acid in Acute Coronary Syndrome) was to compare the efficacy and safety of triple LLT (high-dose, high-intensity statin+ezetimibe+bempedoic acid) versus standard of care (high-dose, high-intensity statin+ezetimibe) after ACS.
25. Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1).
作者: David G Armstrong.;Michael S Conte.;Joseph L Mills.;Matthew T Menard.;Dennis P Orgill.;Robert D Galiano.;Robert S Kirsner.;Alik Farber.;John C Lantis.;Charles M Zelen.;Marissa J Carter.;Caitlin W Hicks.;Richard J Powell.
来源: Circ Cardiovasc Interv. 2026年19卷1期e015648页
People with chronic limb-threatening ischemia lack Food and Drug Administration-approved therapies for wound healing, creating an unmet need for novel approaches. Prior studies of biologics in chronic limb-threatening ischemia have largely targeted end-stage patients with amputation-free survival as the primary outcome. This trial evaluated the efficacy of intramuscular administration of AMG0001, a plasmid encoding human HGF (hepatocyte growth factor), to promote ulcer healing in patients with chronic limb-threatening ischemia and neuroischemic ulcers.
26. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial.
作者: Robert A Lookstein.;Stavros V Konstantinides.;Ido Weinberg.;Suhail Y Dohad.;Zachary Rosol.;Grzegorz Kopeć.;John M Moriarty.;Sahil A Parikh.;Andrew Holden.;Richard N Channick.;Braedon McDonald.;Khanjan H Nagarsheth.;Kei Yamada.;Rachel P Rosovsky.; .
来源: Circulation. 2026年153卷1期21-34页
Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right ventricular (RV) to left ventricular (LV) diameter ratio and are at risk of early clinical decompensation and mortality. Reperfusion therapy aims to rapidly relieve acute RV pressure overload and to normalize hemodynamics. STORM-PE (A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone Versus Anticoagulation Plus Mechanical Aspiration With the Indigo Aspiration System for the Treatment of Intermediate-High Risk Acute Pulmonary Embolism) is the first reported randomized controlled trial to test the efficacy and to evaluate the safety of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) with anticoagulation compared to anticoagulation alone.
27. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
作者: Victorien Monguillon.;Peter J Kelly.;Michelle L O'Donoghue.;Jeong-Gun Park.;Erin A Bohula.;Jeffrey L Saver.;Dan Atar.;Anthony C Keech.;Peter S Sever.;Huei Wang.;Gabriel Paiva da Silva Lima.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2026年153卷2期86-93页
Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear.
28. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
作者: Robin Myte.;Andrea Mattsson.;Matt Poole.;Dustin J Little.;Per Nyström.;Alasdair Henderson.;Brian L Claggett.;Samvel B Gasparyan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2025年18卷12期e013496页
Patients with cardiovascular conditions like heart failure (HF) often exhibit significant heterogeneity of the risk of clinical events. In clinical trials, large risk heterogeneity can result in an underestimation of treatment effects derived from Cox proportional hazards models. This occurs due to selection bias when estimating the hazard ratio, stemming from a disproportionate reduction of event-free patients in the control group compared with an effective active group over time, ultimately reducing the statistical power. Therefore, it is important to explore alternative analysis methods for outcome trials that are robust with respect to risk heterogeneity.
29. The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.
作者: Christopher A Rajkumar.;Michael J Foley.;Fiyyaz Ahmed-Jushuf.;Shayna Chotai.;Florentina A Simader.;Muhammad Mohsin.;Ahmed Salih.;Sashiananthan Ganesananthan.;Nina Bual.;Ricardo Petraco.;Sukhjinder S Nijjer.;Sayan Sen.;Joban Sehmi.;Neil Ruparelia.;Jason N Dungu.;Alamgir Kabir.;Kare Tang.;Reto Gamma.;John R Davies.;Tushar Kotecha.;Graham D Cole.;James P Howard.;Thomas R Keeble.;Gerald J Clesham.;Peter D O'Kane.;Frank E Harrell.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha K Al-Lamee.
来源: Circulation. 2025年152卷22期1541-1551页
Little correlation exists between the burden of ischemia and severity of angina in patients with stable coronary artery disease. This placebo-controlled, n-of-1 study investigated the relationship between ischemia, the collateral circulation, and symptoms in stable coronary artery disease. Additionally, it explored the association between progressive collateral recruitment and ischemic preconditioning.
30. Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.
作者: Josep Rodés-Cabau.;Luis Nombela-Franco.;Ignacio Cruz-Gonzalez.;Benjamin Hibbert.;Xavier Freixa.;Jean-Bernard Masson.;Réda Ibrahim.;Rodrigo Estevez-Loureiro.;Xavier Millan.;Malek Kass.;Jean-Michel Paradis.;Jean Champagne.;Pablo Salinas.;Ana Laffond.;Omar Abdel-Razek.;Marino Labinaz.;Pedro Cepas-Guillen.;Dabit Arzamendi.;Pablo Vidal-Cales.;Marco Pavesi.;Mélanie Côté.;Gilles O'Hara.;Erwan Salaun.
来源: Circulation. 2025年152卷25期1759-1768页
The optimal antithrombotic treatment after transcatheter left atrial appendage closure (LAAC) remains to be determined. The objective of this trial was to compare anticoagulation and antiplatelet therapy for preventing device-related thrombosis (DRT) after LAAC.
31. Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.
作者: Anping Cai.;Antoni Bayes-Genis.;Joanne Ryan.;Yingqing Feng.;James L Januzzi.;Andrew M Tonkin.;Jiazhen Zheng.;Mark R Nelson.;Johannes T Neumann.;Robyn L Woods.;Cammie Tran.;Aletta E Schutte.;Ambarish Pandey.;Lin Yee Chen.;Lin Liu.;Junguo Zhang.;John J McNeil.;Lawrence Beilin.;Hung-Fat Tes.;Gianfranco Parati.;Zhen Zhou.
来源: Circulation. 2025年152卷23期1621-1633页
Blood pressure (BP) management in older adults is complex because of age-related physiological changes and uncertainty around ideal systolic BP (SBP) targets. Heart stress (HS), defined by age-adjusted elevation in NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, may improve cardiovascular disease (CVD) risk stratification and support more individualized BP management.
32. Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT.
作者: Feng Gao.;Xu Tong.;Ming Wei.;Xiaoxi Yao.;Lei Li.;Yuesong Pan.;Baixue Jia.;Thanh N Nguyen.;Ming Yang.;Dapeng Sun.;Ganghua Feng.;Guangxiong Yuan.;Chenghua Xu.;Zhengzhou Yuan.;Yue Wan.;Jing Wang.;Ping Jing.;Xinguang Yang.;Zhilin Wu.;Wei Hu.;Yuanfei Jiang.;Chaobin Wang.;Changming Wen.;Jianjun Tang.;Xiang Luo.;Yingchun Wu.;Ruile Shen.;Tuanyuan Zheng.;Yaxuan Sun.;Mingze Chang.;Yan Liu.;Yang Haihua.;Di Li.;Bo Yin.;Weihua Jia.;Dongjun Wan.;Guodong Xu.;Zaiyu Guo.;Dianjing Sun.;Yang Wang.;Jixin Duan.;Liyu Wang.;Guoqing Wang.;Liping Wei.;Gaoting Ma.;Xiaochuan Huo.;Dapeng Mo.;Ning Ma.;Zeguang Ren.;Liping Liu.;Xingquan Zhao.;Yilong Wang.;Jens Fiehler.;Yongjun Wang.;Zhongrong Miao.; .
来源: Circulation. 2025年152卷20期1397-1407页
The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0-2a) or >70% residual stenosis after thrombectomy.
33. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
作者: Fengwen Zhang.;Jie Dong.;Peijian Wei.;Weiyi Fang.;Hao Hu.;Xiangqing Kong.;Ming Bai.;Jiahua Pan.;Zhiling Luo.;Ping Zhang.;Baiming Qu.;Jinpeng Hu.;Yaoxing Lu.;Chuangshi Wang.;Shouzheng Wang.;Xiangbin Pan.
来源: Circulation. 2026年153卷2期71-81页
Novel biodegradable patent foramen ovale (PFO) closure devices offer a promising therapeutic option. The efficacy and safety of the novel biodegradable devices compared with nitinol devices have not yet been investigated in a randomized clinical trial.
34. Diastolic Blood Pressure and Cognitive Function in Adults With Achieved Systolic Blood Pressure Below 130 mm Hg: Insights From the SPRINT-MIND Trial.
作者: Ruixue Yang.;Zhou Fang.;Daman Yang.;Lei Zhang.;Qiaoxi Yang.;Qianhui Ling.;Xilan Dong.;Miaomiao Zhuang.;Tianchen Guo.;Sifei Chen.;Yufei Ji.;Jun Cai.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷11期e011902页
The potential J-shaped relationship whereby lower diastolic blood pressure (DBP) is associated with a higher risk of adverse cognitive outcomes has raised concerns regarding intensive systolic blood pressure (SBP) lowering. However, the current guidelines advocate a stricter SBP target of <130 mm Hg, with no clear consensus on a DBP target, especially with respect to brain health. The present study aimed to determine the relationship between treated DBP and cognitive function, as well as cerebral perfusion and structure, in adults who achieved an SBP <130 mm Hg.
35. Complete Revascularization in Older Patients With Myocardial Infarction With or Without Complex Nonculprit Lesions.
作者: Alberto Sarti.;Andrea Erriquez.;Beatrice Dal Passo.;Gianni Casella.;Vincenzo Guiducci.;Raul Moreno.;Javier Escaned.;Federico Marchini.;Marta Cocco.;Filippo Maria Verardi.;Stefano Clò.;Serena Caglioni.;Jacopo Farina.;Emanuele Barbato.;Giuseppe Vadalà.;Caterina Cavazza.;Alessandro Capecchi.;Francesco Gallo.;Gianluca Campo.;Simone Biscaglia.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015902页
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease. Whether this result applies equally to patients at higher risk of ischemic events due to nonculprit lesion complexity is unclear.
36. Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock.
作者: Christian Jung.;Alexander Lang.;Dragos Andrei Duse.;Raphael Romano Bruno.;Janine Pöss.;Georg Wolff.;Uta Ceglarek.;Uwe Zeymer.;Georg Fuernau.;Elric Zweck.;Steffen Desch.;Anne Freund.;Berend Isermann.;Susanne Pfeiler.;Bernhard Wernly.;Malte Kelm.;Holger Thiele.;Norbert Gerdes.
来源: Circ Heart Fail. 2025年18卷12期e012890页
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) leading to poor outcomes. Specific biomarkers, with subsequent validation of their prognostic relevance in CS, are urgently needed to improve therapies and outcomes. Accordingly, the present study investigated the plasma proteome using proximity extension assay technology to identify novel specific biomarkers with subsequent validation of their prognostic relevance in CS.
37. Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.
作者: Masaharu Masuda.;Yasuhiro Matsuda.;Hiroyuki Uematsu.;Hirotaka Ooka.;Satoshi Kudo.;Mizuki Ochi.;Toshiaki Mano.;Akihiro Sunaga.;Nobuaki Tanaka.;Tetsuya Watanabe.;Hitoshi Minamiguchi.;Yasuyuki Egami.;Takafumi Oka.;Tomoko Minamisaka.;Takashi Kanda.;Masato Okada.;Masato Kawasaki.;Koji Tanaka.;Nobuhiko Makino.;Hirota Kida.;Shungo Hikoso.;Tomoharu Dohi.;Koichi Inoue.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e014210页
In the randomized controlled SUPPRESS-AF trial (Efficacy and Safety of Left Atrial Low-voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrillation), the efficacy of low-voltage-area (LVA) ablation was highly dependent on the degree of atrial remodeling, while the efficacy was not statistically significant in total patients. This subanalysis of the SUPPRESS-AF trial aimed to compare the efficacy of LVA ablation in patient groups classified by left atrial diameter (LAD), which is a commonly used atrial remodeling index.
38. Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation.
作者: Masahiro Natsuaki.;Hirotoshi Watanabe.;Takeshi Morimoto.;Ko Yamamoto.;Yuki Obayashi.;Ryusuke Nishikawa.;Tomoya Kimura.;Kenji Ando.;Satoru Suwa.;Tsuyoshi Isawa.;Hiroyuki Takenaka.;Tetsuya Ishikawa.;Toshihiro Tamura.;Kandoh Kawahatsu.;Fujio Hayashi.;Masaharu Akao.;Takeshi Serikawa.;Hiroyoshi Mori.;Takayuki Kawamura.;Arata Hagikura.;Naoki Shibata.;Koh Ono.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015495页
There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year after percutaneous coronary intervention when dual therapy with OAC and clopidogrel was recommended.
39. Patterns of Restenosis After Left Main Bifurcation Single- or Dual-Stenting: An EBC MAIN Trial Subanalysis.
作者: Annette Maznyczka.;Sandeep Arunothayaraj.;Adrian P Banning.;Thomas Schmitz.;Adrian Wlodarczak.;Marc Silvestri.;Mohaned Egred.;René Koning.;Mark S Spence.;Marie-Claude Morice.;Thierry Lefevre.;Miroslaw Ferenc.;James Cockburn.;Andrejs Erglis.;Philippe Brunel.;Francesco Burzotta.;Evgeny Kretov.;Thomas Hovasse.;Manuel Pan.;Gerald Clesham.;Alaide Chieffo.;Darren Mylotte.;Mitchell Lindsay.;Evald H Christiansen.;Frédéric Bouisset.;Beatriz Vaquerizo.;Jens Flensted Lassen.;Olivier Darremont.;Yves Louvard.;Goran Stankovic.;David Hildick-Smith.; .
来源: Circ Cardiovasc Interv. 2025年18卷11期e015546页
In the randomized EBC MAIN trial (European Bifurcation Club Left Main Coronary Stent), target lesion revascularization at 3 years poststenting of left main (LM) bifurcations was more frequent with upfront dual-stenting compared with the stepwise provisional approach. Restenosis location and its relation to stent technique are poorly characterized. The aim of this study was to investigate restenosis location after LM bifurcation stenting, and the impact of stent implantation technique.
40. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
作者: Brian G DeRubertis.;Ramon L Varcoe.;Prakash Krishnan.;Marc P Bonaca.;David J O'Connor.;Richard Pin.;David C Metzger.;Andrew Holden.;Jen-Kuang Lee.;Osamu Iida.;Ehrin J Armstrong.;Steven W C Kum.;Raghu Kolluri.;Danielle R Bajakian.;Lawrence A Garcia.;Mehdi H Shishehbor.;Shawn Yu.;Karine Ruster.;Brad J Martinsen.;Zsuzsanna Igyarto.;Sahil A Parikh.
来源: Circulation. 2025年152卷15期1076-1086页
Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK randomized controlled trial (Pivotal Investigation of Safety and Efficacy of BRS Treatment-Below the Knee), the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions. This report presents the 2-year safety and efficacy outcomes of the Esprit BTK DRS system in the LIFE-BTK randomized trial comparing DRS with PTA for treatment of infrapopliteal vessels and CLTI.
|